ClinicalTrials.gg
Not yet recruitingNCT05524974Updated Sep 1, 2022

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

A Phase 2 interventional study of Camrelizumab and Oxaliplatin in Locally Advanced Gastric Cancer, sponsored by Fujian Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-01.

Sponsored by Fujian Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
203
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies testing camrelizumab in Stomach Neoplasms — 8 open to participants now, 11 under way, 2 of them phase 3. camrelizumab · Stomach Neoplasms.

Planned enrollment
4th of 33
203 · median 46
Started
2022
with 4 others
Phase 2
24 of 33
4 open now
Primary completion
2024-09
later than 5 of 10 live
Registered
27th of 33
by date
Lead sponsor
3 of 33
Fujian Medical University

Among the 33 studies testing camrelizumab in Stomach Neoplasms, this one is the 4th largest by planned enrollment, is one of 5 that started in 2022, is one of 24 in phase 2, reaches primary completion later than 5 of the 10 other live ones, and was the 27th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 33 studies testing camrelizumab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing camrelizumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes

03

Conditions studied

  • Locally Advanced Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age from 18 to 75 years, all sex;
  2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by histology or cytology;
  3. CT/MRI,PET-CT or laparoscopic exploration were used to confirm the diagnosis of gastric cancer staging as cT2-4a and/or N+ and M0 before operation.;
  4. at least should be detected by CT/MRI examination in accordance with the RECIST1.1.(CT scan of tumor lesion length≥10mm,CT scan short diameter of lymph node≥15mm,scan slice thickness 5mm);
  5. (Eastern Cooperative Oncology Group)PS(Performance Status):0-1 scores;
  6. the expected survival time is more than 12 weeks;
  7. the main organ function is normal, which should meet the following criteria: (1)(1)blood routine examination standards should be met(no blood transfusion within 14 days)

    1. HB≥100g/L,
    2. WBC≥3×109/L
    3. ≥1.5×109/L,
    4. ≥100×109/L; (2)biochemical examination shall comply with the following criteria:

    <!-- -->

    1. BIL \<1.5normal upper limit(),
    2. 和AST\<2.5ULN,GPT≤1.5×ULN;
    3. serum Cr≤1ULN, rate>60ml/min(Cockcroft-Gault formula)
  8. women of childbearing age must have a pregnancy test in 7 days before entering the group (in serum), and the results were negative, and willing to use appropriate during the study period and the last 8 weeks after giving drug; men should have the surgical sterilization, or adopt the appropriate contraceptive methods during the test and the last 8 weeks after giving drug.;
  9. No other clinical studies were conducted before and during the treatment; participants is willing to participate in this study, sign the , have good compliance, cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of chemotherapy, radiotherapy, targeted drug therapy or immunotherapy
  2. Patients with for surgical treatment and chemotherapy or whose physical condition and organ function do not allow for major abdominal surgery;
  3. patients with ;
  4. Having any active diseases or a history of autoimmune diseases (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes); Patients with vitiligo or cured childhood asthma/allergies who did not need any intervention in adulthood were excluded; Autoimmune hypothyroidism treated with a stable dose of thyroid replacement hormone; Type 1 diabetes with stable doses of insulin;
  5. A history of immunodeficiency, including testing positive, or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation and bone marrow transplantation;
  6. Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease; Jaundice or obstruction of the digestive tract with severe infection;
  7. pregnant or lactating women;
  8. The blood pressure of patients with hypertension cannot be reduced to the normal range by the antihypertensive drugs (systolic pressure >140 mmHg, diastolic pressure >90 mmHg);
  9. With Ⅰ magnitude of coronary heart disease, arrhythmia (including protracted between male > 450 ms, women > 470 ms) and cardiac insufficiency;
  10. Patients have a clear tendency with gastrointestinal bleeding, including the following situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena and hematemesis history in 2 months; and patients with fecal occult blood (+) and coagulation dysfunction ((international normalized ratio)>1.5, APTT(activated partial thromboplastin time)>1.5 ), with bleeding tendency;;
  11. Subjects have failed to control good cardiovascular clinical symptoms or disease, including but not limited to: such as: (1) the class II heart failure or above (2) unstable angina pectoris (3) MI occurred within 1 year (4) have clinical significance of supraventricular or ventricular arrhythmias without clinical intervention on or after clinical intervention is still poorly controlled;
  12. History of interstitial lung disease (except radiation pneumonia without hormone therapy), and history of non-infectious pneumonia;
  13. Patients are positive of urine protein (urine protein detection 2+ or above, or 24 hours urine protein quantitative >1.0g);
  14. A person who has previously been allergic to any component of the drug in this study; The researchers consider those who were not suitable for inclusion.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
203 participants (estimated)

Study arms

  • Experimental
    Camrelizumab combined with Oxplatin and S-1 for Immune Genotypes

    Drug: Camrelizumab · Drug: Oxaliplatin · Drug: S1

  • Active comparator
    Oxplatin and S-1 for Immune Genotypes

    Drug: Oxaliplatin · Drug: S1

  • Experimental
    Apatinib Mesylate combined with Oxplatin and S-1 for Mesenchymal Genotypes

    Drug: Oxaliplatin · Drug: S1 · Drug: Apatinib Mesylate

  • Active comparator
    Oxplatin and S-1 for Mesenchymal Genotypes

    Drug: Oxaliplatin · Drug: S1

  • Experimental
    Nab-paclitaxel combined with Oxplatin and S-1 for Classic Genotypes

    Drug: Oxaliplatin · Drug: S1 · Drug: Nab paclitaxel

  • Active comparator
    Oxplatin and S-1 for Classic Genotypes

    Drug: Oxaliplatin · Drug: S1

  • Active comparator
    Oxplatin and S-1 for Metabolic Genotypes

    Drug: Oxaliplatin · Drug: S1

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate

    Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST

    Time frame: 4 months

Secondary outcomes

  1. R0 resection rate

    The surgical procedure was total or subtotal gastrectomy with 3 weeks after total neoadjuvant therapy.

    Time frame: 4 months

  2. Disease control rate

    Time frame: 4 months

  3. 1-year and 3-year OS/DFS

    Time frame: 1 and 3 years

  4. adverse event

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

    Time frame: 3 years

  5. overall postoperative morbidity rates

    Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery.

    Time frame: 30 days

  6. 30 days mortality rates

    Defined as the event observed within 30 days after surgery.

    Time frame: 30 days

  7. Duration of postoperative hospital stay

    Duration of postoperative hospital stay in days is used to assess the postoperative recovery course.

    Time frame: 30 days

  8. The prediction performance of Exosome contents (including proteins, nucleic acids)

    Exosomes were isolated using a Backman Optima XPN-100 instrument. The exosomes morphology was characterized using a HT7700 transmission electron microscope (Hitachi, Co. Ltd., Japan). Fluorescent spectra were recorded using a F96 Pro fluorospectrophotometer (Shanghai Lengguang Technology). The concentration and size distribution of the exosomes were quantified using nanoparticle tracking analysis (NanoSight NS 300, Malvern Instrument). The obtained results were subjected to biostatistical analysis, such as heat map generation, ROC curve establishment, and confusion matrix.

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2022; primary completion for Sep 2024, 24 months later.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 24 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Sep 1, 2022
StartEst.
Sep 1, 2022
Primary completionEst.
Sep 1, 2024
CompletionEst.
Sep 1, 2027
Last update
Sep 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05524974
Responsible party
Chang-Ming Huang, Prof. (Director of gastric surgery, Fujian Medical University) — Principal investigator
First posted
Sep 1, 2022
Start date
Sep 1, 2022 (estimated)
Primary completion
Sep 1, 2024 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Sep 1, 2022

Study contacts

Chang-Ming Huang, PhD
Contact
hcmlr2002@163.com
8613805069676
Hualong Zheng, PhD
Contact
291167038@qq.com
18359190587
Chang-Ming Huang, phD
principal investigator · Fujian Medical University Union Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib · Albumin-Bound Paclitaxel

Start the discussion